Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 14/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14153091 | 0.93 | TP53 (0.52) | TP53HDAC6HDAC1HDAC8GRM5 | |
| SCHEMBL16104094 | 0.86 | HDAC6 (0.61) | TP53HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL4957967 | 0.83 | NPC1 (0.52) | TP53HDAC6HDAC1GRM5HDAC4 | |
| SCHEMBL24660166 | 0.82 | TP53 (0.50) | TP53HDAC6HDAC1HDAC8GRM5 | |
| SCHEMBL29176843 | 0.81 | L3MBTL1 (0.44) | TP53HDAC6HDAC1HDAC8NPC1 | |
| SCHEMBL14061619 | 0.81 | HDAC1 (0.46) | TP53HDAC6HDAC1HDAC8GRM5 | |
| Hydrochloric Acid SCHEMBL29463520 | 0.81 | TP53 (0.49) | TP53HDAC6HDAC1HDAC8GRM5 | |
| Hydrochloric Acid SCHEMBL28701616 | 0.81 | TP53 (0.49) | TP53HDAC6HDAC1HDAC8GRM5 | |
| SCHEMBL3634573 | 0.80 | NR1H4 (0.57) | TP53HDAC4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30041989 | 0.78 | CHRNB2 (0.53) | TP53HDAC6HDAC1HDAC8GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| CN-1905868-A | DPP-IV inhibitors | GRAFFINITY PHARMACEUTICALS AG (CH) | 2007-01-31 | — | — | CN | disclosed |
| EP-1613304-A1 | DPP-IV INHIBITORS | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | TP53 4738/4885HDAC6 1507/4885HDAC1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.